Company Presentation

GeNeuro is a Phase2 clinical-stage company that develops antibodies to neutralize patient-produced pathogenic proteins that fuel a great number of neurodegenerative and autoimmune diseases.
GeNeuro leverages this approach against diseases such as multiple sclerosis, amyotrophic lateral sclerosis and, more recently, post-COVID neuropsychiatric syndromes.